Genoway is a leading biotechnology company dedicated to the design and development of high-value, genetically engineered research models, primarily mice and rats, as well as cell lines. Serving academic researchers, pharmaceutical companies, and biotech organizations worldwide, Genoway provides critical tools and preclinical services for drug discovery, target validation, and understanding human diseases. Their expertise spans a wide range of genetic modification technologies, including CRISPR/Cas9, homologous recombination, and transgenesis, enabling the creation of customized models tailored to specific research needs.
The Lyon headquarters serves as the central nexus for Genoway's research and development, complex project management, global sales and marketing coordination, customer relations, and corporate administration. It is where core scientific innovations in genetic engineering and model creation are driven.
The facility is equipped with advanced, state-of-the-art laboratories essential for molecular biology, cell culture, embryology, and the development and housing of genetically engineered rodent models. This includes specialized suites for transgenesis, genome editing (e.g., CRISPR/Cas9), and preclinical phenotyping.
The work culture at Genoway's headquarters is characterized by a strong emphasis on scientific rigor, innovation, precision, and collaboration. It fosters a problem-solving environment where scientists and technicians work on cutting-edge genetic technologies to meet complex client requirements, adhering to high ethical standards in animal research.
Locating in Lyon provides Genoway with significant advantages, including access to a rich ecosystem of life science research institutions, a skilled talent pool, potential academic and industry collaborations, and robust infrastructure supporting biotech operations.
Genoway serves a global clientele, providing its genetically engineered models and preclinical services to academic institutions, pharmaceutical companies, and biotech organizations across North America, Europe, Asia-Pacific, and other regions. Its international functions are supported through direct sales, project management from its French headquarters, its US presence, and a network of collaborators and distributors to ensure worldwide accessibility to its advanced genetic engineering capabilities and research models.
11 Rue des Petites Industries, Bâtiment C
Lyon
Auvergne-Rhône-Alpes
France
Address: Presence within Research Triangle Park (Specific suite/building address for business development office not publicly detailed)
To enhance Genoway's market penetration in North America, provide localized client engagement, and facilitate easier access to its specialized genetic engineering services for US and Canadian researchers.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, genOway' leadership includes:
genOway has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major C-suite executive new hires or departures announced by Genoway in the last 12 months, suggesting stability in the top leadership team.
Discover the tools genOway uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Genoway typically utilizes an email format of [first_initial].[last_name]@genoway.com for its employees. This standardized professional format facilitates direct communication with team members across various departments.
[first_initial].[last_name]@genoway.com
Format
a.fraichard@genoway.com
Example
90%
Success rate
Actusnews Wire • March 27, 2024
Genoway reported its annual financial results for 2023, highlighting revenue growth and outlining its strategic outlook and development plans for 2024, focusing on catalog expansion and new technological platforms....more
Actusnews Wire • December 20, 2023
Genoway announced the successful completion of a rights issue, raising €2.0 million to support its growth strategy, R&D investments, and expansion of its preclinical model offerings....more
Actusnews Wire • September 27, 2023
Genoway released its financial results for the first half of 2023, detailing performance and progress in its key market segments for genetically engineered models....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including genOway, are just a search away.